Matches in SemOpenAlex for { <https://semopenalex.org/work/W3115114141> ?p ?o ?g. }
- W3115114141 endingPage "661" @default.
- W3115114141 startingPage "644" @default.
- W3115114141 abstract "The phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling pathway is a frequently dysregulated pathway in human cancer, and PI3Kα is one of the most frequently mutated kinases in human cancer. A PI3Kα-selective inhibitor may provide the opportunity to spare patients the side effects associated with broader inhibition of the class I PI3K family. Here, we describe our efforts to discover a PI3Kα-selective inhibitor by applying structure-based drug design (SBDD) and computational analysis. A novel series of compounds, exemplified by 2,2-difluoroethyl (3S)-3-{[2′-amino-5-fluoro-2-(morpholin-4-yl)-4,5′-bipyrimidin-6-yl]amino}-3-(hydroxymethyl)pyrrolidine-1-carboxylate (1) (PF-06843195), with high PI3Kα potency and unique PI3K isoform and mTOR selectivity were discovered. We describe here the details of the design and synthesis program that lead to the discovery of 1." @default.
- W3115114141 created "2021-01-05" @default.
- W3115114141 creator A5002423487 @default.
- W3115114141 creator A5004383407 @default.
- W3115114141 creator A5006518535 @default.
- W3115114141 creator A5008544946 @default.
- W3115114141 creator A5010968025 @default.
- W3115114141 creator A5014715629 @default.
- W3115114141 creator A5016460317 @default.
- W3115114141 creator A5017360203 @default.
- W3115114141 creator A5017395933 @default.
- W3115114141 creator A5018283590 @default.
- W3115114141 creator A5018485011 @default.
- W3115114141 creator A5021258557 @default.
- W3115114141 creator A5026356938 @default.
- W3115114141 creator A5027358753 @default.
- W3115114141 creator A5031608383 @default.
- W3115114141 creator A5031861539 @default.
- W3115114141 creator A5035042950 @default.
- W3115114141 creator A5040253718 @default.
- W3115114141 creator A5043364506 @default.
- W3115114141 creator A5043590615 @default.
- W3115114141 creator A5044435389 @default.
- W3115114141 creator A5045007590 @default.
- W3115114141 creator A5045280982 @default.
- W3115114141 creator A5045471230 @default.
- W3115114141 creator A5045864062 @default.
- W3115114141 creator A5051693801 @default.
- W3115114141 creator A5052326591 @default.
- W3115114141 creator A5056520253 @default.
- W3115114141 creator A5056628506 @default.
- W3115114141 creator A5059444973 @default.
- W3115114141 creator A5059699253 @default.
- W3115114141 creator A5059826923 @default.
- W3115114141 creator A5062811351 @default.
- W3115114141 creator A5066089549 @default.
- W3115114141 creator A5067218552 @default.
- W3115114141 creator A5070956637 @default.
- W3115114141 creator A5073100591 @default.
- W3115114141 creator A5088905699 @default.
- W3115114141 creator A5089696102 @default.
- W3115114141 date "2020-12-24" @default.
- W3115114141 modified "2023-10-01" @default.
- W3115114141 title "Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)" @default.
- W3115114141 cites W1979937839 @default.
- W3115114141 cites W1996648165 @default.
- W3115114141 cites W2009886463 @default.
- W3115114141 cites W2012241102 @default.
- W3115114141 cites W2018872626 @default.
- W3115114141 cites W2025188980 @default.
- W3115114141 cites W2039258567 @default.
- W3115114141 cites W2041366211 @default.
- W3115114141 cites W2062441961 @default.
- W3115114141 cites W2067342462 @default.
- W3115114141 cites W2077451485 @default.
- W3115114141 cites W2082473218 @default.
- W3115114141 cites W2088460013 @default.
- W3115114141 cites W2101982508 @default.
- W3115114141 cites W2119855881 @default.
- W3115114141 cites W2126839635 @default.
- W3115114141 cites W2128855114 @default.
- W3115114141 cites W2129172946 @default.
- W3115114141 cites W2141125222 @default.
- W3115114141 cites W2141307152 @default.
- W3115114141 cites W2160883729 @default.
- W3115114141 cites W2320903282 @default.
- W3115114141 cites W2744377419 @default.
- W3115114141 cites W2786945112 @default.
- W3115114141 cites W2794867021 @default.
- W3115114141 cites W2905937602 @default.
- W3115114141 cites W2949521120 @default.
- W3115114141 cites W3023538604 @default.
- W3115114141 cites W4254208211 @default.
- W3115114141 cites W44426163 @default.
- W3115114141 doi "https://doi.org/10.1021/acs.jmedchem.0c01652" @default.
- W3115114141 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33356246" @default.
- W3115114141 hasPublicationYear "2020" @default.
- W3115114141 type Work @default.
- W3115114141 sameAs 3115114141 @default.
- W3115114141 citedByCount "20" @default.
- W3115114141 countsByYear W31151141412021 @default.
- W3115114141 countsByYear W31151141412022 @default.
- W3115114141 countsByYear W31151141412023 @default.
- W3115114141 crossrefType "journal-article" @default.
- W3115114141 hasAuthorship W3115114141A5002423487 @default.
- W3115114141 hasAuthorship W3115114141A5004383407 @default.
- W3115114141 hasAuthorship W3115114141A5006518535 @default.
- W3115114141 hasAuthorship W3115114141A5008544946 @default.
- W3115114141 hasAuthorship W3115114141A5010968025 @default.
- W3115114141 hasAuthorship W3115114141A5014715629 @default.
- W3115114141 hasAuthorship W3115114141A5016460317 @default.
- W3115114141 hasAuthorship W3115114141A5017360203 @default.
- W3115114141 hasAuthorship W3115114141A5017395933 @default.
- W3115114141 hasAuthorship W3115114141A5018283590 @default.
- W3115114141 hasAuthorship W3115114141A5018485011 @default.
- W3115114141 hasAuthorship W3115114141A5021258557 @default.
- W3115114141 hasAuthorship W3115114141A5026356938 @default.
- W3115114141 hasAuthorship W3115114141A5027358753 @default.